The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status

Table 2

The clinicopathological features of HER2-low and HER2-negative subtypes in considering the HR expression status.

Clinicopathological characteristics	Hormone receptors negative			Hormone receptors positive
	HER2 low (%)	HER2 negative (%)		HER2 low (%)	HER2 negative (%)
Age			0.3			0.5
<50yo	46.1	47.5		47.1	48.2
>50yo	53.9	52.5		52.9	51.8
SBR grade			<0.001			<0.001
I	41.2	22.5		28.1	1.0
II	35.9	53.5		49.7	35.3
III	19.3	20.8		20.5	59.7
NA	3.6	3.1		1.6	4.0
Tumor size			<0.001			<0.001
T0	0.0	0.4		0.0	1.0
T1	18.6	23.4		13.0	14.9
T2	30.9	40.7		24.9	46.8
T3	7.4	6.9		10.3	10.9
T4	1.3	6.7		1.6	10.0
TX	41.7	21.9		50.3	16.4
Lymph node			<0.001			0.005
N+	39.9	51.4		66.5	50.2
N0	38.2	40.4		28.6	42.8
NX	21.9	8.2		4.9	7.0
Tumor stage			0.001			<0.001
I	9.6	11.6		4.9	7.5
II	19.2	31.0		13.0	39.8
III	19.6	28.8		22.7	26.9
IV	1.1	2.8		1.1	4.0
NA	50.6	25.7		58.4	21.9
ER			—			—
Negative	—	—		100.0	100.0
Positive	100.0	100.0		—	—
PR			0.005			—
Negative	3.4	6.7		100.0	100.0
Positive	96.6	93.1		—	—
NA	0.0	0.3		—	—
Ki67			0.004			<0.001
<20%	39.2	45.6		5.4	10.4
>20%	49.5	41.1		90.8	62.7
NA	11.2	13.4		3.8	26.9

The values in bold presented in Table 2 indicate that the p value is less than 0.05.